M. S. Muldahmetov
Research Subjects
M. S. Muldahmetov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- B. K. Nurmagambetova
1НАО «Медицинский университет Астана», г. Астана, Республика Казахстан
2 shared publications - R.R. Nussupova
NCJSC «Astana Medical University», Astana, the Republic of Kazakhstan
2 shared publications - Фатима Сайцилиновна Алиева
Astana Medical University
2 shared publications - Aidos Bolatov
Shenzhen University Medical School, Shenzhen University, Shenzhen, China
1 shared publication - Askhat Zhakupov
Clinical Academic Department of Laboratory Medicine, Pathology, and Genetics “University Medical Center” Corporate Fund Astana Kazakhstan
1 shared publication L.A. Pack
National Research Oncology Center, Astana, the Republic of Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 28 February 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 1(27),p. 17-25
GENETIC ANALYSIS OF TP53 AND CTNNB1 MUTATIONS IN PEDIATRIC MEDULLOBLASTOMA: A STUDY FROM KAZAKHSTAN
Background: Medulloblastoma is the most common malignant pediatric brain tumor, exhibiting significant genetic heterogeneity. Mutations in TP53 and CTNNB1 have been implicated in tumorigenesis, prognosis, and treatment response. However, their precise role in medulloblastoma remains incompletely understood. This study aimed to analyze TP53 and CTNNB1 variants in Kazakhstani pediatric medulloblastoma patients and assess their clinical significance. Methods: A retrospective analysis was conducted on 33 pediatric medulloblastoma cases from 2015 to 2023. Formalin-fixed paraffin-embedded (FFPE) tumor tissues were used for DNA extraction and Sanger sequencing of TP53 (exons 4, 5, 6, 7, 8) and CTNNB1 (exons 3, 4). Genetic variants were classified using ClinVar, ACMG guidelines, and AMP classification. Statistical associations between mutations, clinical features, and outcomes were assessed. Results: Among 28 successfully sequenced cases, seven TP53 variants were identified: c.214_215delinsTG (p.Pro72Cys), c.215_216delinsGT (p.Pro72Arg), c.300G>A (p.Gln100=), c.356C>G (p.Ala119Gly), c.357C>G (p.Ala119=), c.782+10C>G (splice-region), and c.817C>G (p.Arg273Gly). The p.Pro72Arg variant was significantly associated with metastasis (p = 0.008). The c.356C>G (p.Ala119Gly) variant, previously linked to Li-Fraumeni syndrome, was detected in one case. No variants were found in exons 3 and 4 of CTNNB1. Conclusion: This study highlights the role of TP53 mutations in medulloblastoma progression, particularly their association with metastasis. The absence of CTNNB1 mutations suggests that WNT pathway activation may be rare in this cohort. Further studies with larger sample sizes and functional validation are needed to clarify the prognostic and therapeutic implications of TP53 mutations in pediatric medulloblastoma. Введение: Медуллобластома — самая распространённая злокачественная опухоль головного мозга у детей, характеризующаяся значительным генетическим разнообразием. Мутации в генах TP53 и CTNNB1 играют роль в опухолеобразовании, прогнозе и ответе на лечение. Однако их точная роль при медуллобластоме до конца не изучена. Целью настоящего исследования явилось изучение вариантов TP53 и CTNNB1 у казахстанских детей с медуллобластомой и оценка их клинического значения. Методы: Был проведён ретроспективный анализ 33 случаев детской медуллобластомы за период с 2015 по 2023 год. Для экстракции ДНК и последующего секвенирования по Сэнгеру генов TP53 (экзоны 4, 5, 6, 7, 8) и CTNNB1 (экзоны 3, 4) использовались опухолевые ткани, фиксированные в формалине и залитые в парафин (FFPE). Генетические варианты классифицировались согласно базе данных ClinVar, рекомендациям ACMG и классификации AMP. Статистическая связь между мутациями, клиническими характеристиками и исходами была проанализирована. Результаты: Из 28 успешно секвенированных образцов были выявлены семь вариантов TP53: c.214_215delinsTG (p.Pro72Cys), c.215_216delinsGT (p.Pro72Arg), c.300G>A (p.Gln100=), c.356C>G (p.Ala119Gly), c.357C>G (p.Ala119=), c.782+10C>G (область сплайсинга) и c.817C>G (p.Arg273Gly). Вариант p.Pro72Arg показал значимую ассоциацию с метастазированием (p = 0.008). Вариант c.356C>G (p.Ala119Gly), ранее связанный с синдромом Ли-Фраумени, был выявлен в одном случае. В экзонах 3 и 4 гена CTNNB1 мутаций не обнаружено. Заключение: Данное исследование подчёркивает роль мутаций TP53 в прогрессировании медуллобластомы, в особенности их связь с метастазированием. Отсутствие мутаций в CTNNB1 указывает на редкость активации WNT-пути в данной когорте. Для более точной оценки прогностического и терапевтического значения мутаций TP53 при детской медуллобластоме необходимы дальнейшие исследования с большим числом пациентов и функциональной валидацией. Кіріспе: Медуллобластома — балалар арасында ең жиі кездесетін қатерлі ми ісігі болып табылады және генетикалық тұрғыдан алғанда айтарлықтай әртүрлілікпен сипатталады. TP53 және CTNNB1 гендеріндегі мутациялар ісіктің пайда болуына, болжамына және емге жауап беруіне әсер етуі мүмкін. Алайда, бұл мутациялардың медуллобластома кезіндегі нақты рөлі толық анықталмаған. Осы зерттеудің мақсаты — Қазақстандық балалар арасындағы медуллобластома жағдайларында TP53...
- 28 February 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 1(27),p. 17-25
Open AccessGENETIC ANALYSIS OF TP53 AND CTNNB1 MUTATIONS IN PEDIATRIC MEDULLOBLASTOMA: A STUDY FROM KAZAKHSTAN
Background: Medulloblastoma is the most common malignant pediatric brain tumor, exhibiting significant genetic heterogeneity. Mutations in TP53 and CTNNB1 have been implicated in tumorigenesis, prognosis, and treatment response. However, their precise role in medulloblastoma remains incompletely understood. This study aimed to analyze TP53 and CTNNB1 variants in Kazakhstani pediatric medulloblastoma patients and assess their clinical significance. Methods: A retrospective analysis was conducted on 33 pediatric medulloblastoma cases from 2015 to 2023. Formalin-fixed paraffin-embedded (FFPE) tumor tissues were used for DNA extraction and Sanger sequencing of TP53 (exons 4, 5, 6, 7, 8) and CTNNB1 (exons 3, 4). Genetic variants were classified using ClinVar, ACMG guidelines, and AMP classification. Statistical associations between mutations, clinical features, and outcomes were assessed. Results: Among 28 successfully sequenced cases, seven TP53 variants were identified: c.214_215delinsTG (p.Pro72Cys), c.215_216delinsGT (p.Pro72Arg), c.300G>A (p.Gln100=), c.356C>G (p.Ala119Gly), c.357C>G (p.Ala119=), c.782+10C>G (splice-region), and c.817C>G (p.Arg273Gly). The p.Pro72Arg variant was significantly associated with metastasis (p = 0.008). The c.356C>G (p.Ala119Gly) variant, previously linked to Li-Fraumeni syndrome, was detected in one case. No variants were found in exons 3 and 4 of CTNNB1. Conclusion: This study highlights the role of TP53 mutations in medulloblastoma progression, particularly their association with metastasis. The absence of CTNNB1 mutations suggests that WNT pathway activation may be rare in this cohort. Further studies with larger sample sizes and functional validation are needed to clarify the prognostic and therapeutic implications of TP53 mutations in pediatric medulloblastoma. Введение: Медуллобластома — самая распространённая злокачественная опухоль головного мозга у детей, характеризующаяся значительным генетическим разнообразием. Мутации в генах TP53 и CTNNB1 играют роль в опухолеобразовании, прогнозе и ответе на лечение. Однако их точная роль при медуллобластоме до конца не изучена. Целью настоящего исследования явилось изучение вариантов TP53 и CTNNB1 у казахстанских детей с медуллобластомой и оценка их клинического значения. Методы: Был проведён ретроспективный анализ 33 случаев детской медуллобластомы за период с 2015 по 2023 год. Для экстракции ДНК и последующего секвенирования по Сэнгеру генов TP53 (экзоны 4, 5, 6, 7, 8) и CTNNB1 (экзоны 3, 4) использовались опухолевые ткани, фиксированные в формалине и залитые в парафин (FFPE). Генетические варианты классифицировались согласно базе данных ClinVar, рекомендациям ACMG и классификации AMP. Статистическая связь между мутациями, клиническими характеристиками и исходами была проанализирована. Результаты: Из 28 успешно секвенированных образцов были выявлены семь вариантов TP53: c.214_215delinsTG (p.Pro72Cys), c.215_216delinsGT (p.Pro72Arg), c.300G>A (p.Gln100=), c.356C>G (p.Ala119Gly), c.357C>G (p.Ala119=), c.782+10C>G (область сплайсинга) и c.817C>G (p.Arg273Gly). Вариант p.Pro72Arg показал значимую ассоциацию с метастазированием (p = 0.008). Вариант c.356C>G (p.Ala119Gly), ранее связанный с синдромом Ли-Фраумени, был выявлен в одном случае. В экзонах 3 и 4 гена CTNNB1 мутаций не обнаружено. Заключение: Данное исследование подчёркивает роль мутаций TP53 в прогрессировании медуллобластомы, в особенности их связь с метастазированием. Отсутствие мутаций в CTNNB1 указывает на редкость активации WNT-пути в данной когорте. Для более точной оценки прогностического и терапевтического значения мутаций TP53 при детской медуллобластоме необходимы дальнейшие исследования с большим числом пациентов и функциональной валидацией. Кіріспе: Медуллобластома — балалар арасында ең жиі кездесетін қатерлі ми ісігі болып табылады және генетикалық тұрғыдан алғанда айтарлықтай әртүрлілікпен сипатталады. TP53 және CTNNB1 гендеріндегі мутациялар ісіктің пайда болуына, болжамына және емге жауап беруіне әсер етуі мүмкін. Алайда, бұл мутациялардың медуллобластома кезіндегі нақты рөлі толық анықталмаған. Осы зерттеудің мақсаты — Қазақстандық балалар арасындағы медуллобластома жағдайларында TP53...
- Open Access
- 31 October 2022
- Published by Semey Medical University in Наука и здравоохранение
- No. 5(24),p. 166-178
ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ МЕДУЛЛОБЛАСТОМЫ У ДЕТЕЙ И ПОДХОДЫ К ЕЕ ЛЕЧЕНИЮ. ОБЗОР ЛИТЕРАТУРЫ.
Актуальность:Медуллобластома – одна из наиболее распространенных злокачественных новообразований ЦНС в детском возрасте. Генетические особенности заболевания могут играть важную роль в определении подходов к лечению, но до настоящего времени этот аспект изучен недостаточно. Цель: Общая характеристика современных сведений о генетических вариантах медуллобластомы в контексте возможности целенаправленного формирования траектории лечения. Стратегия поиска: Проведен поиск научных публикаций в поисковых системах PubMed, eLibrary.ru, Google Scholar. Проанализирован ряд оригинальных публикаций и обзоров по направлению исследования за 2012-2022 гг, но также были включены публикации ранее 2012 года, так как они содержат информацию, касательно данной патологии в детском возрасте и классические базовые подходы в терапии и стратификации болезни. Отбор публикаций осуществлялся в соответствии с целью обзора – максимально полной и компактной характеристики генетики медуллобластомы в соответствии с современным лечением. Результаты и выводы: В целом в настоящее время имеются существенные основания для разработки дифференцированных подходов к лечению МБ у детей, основанных на различных видах побочных действий на лучевую и химиотерапию. Однако даже в мировой медицине практическое использование таких подходов ограничено. В настоящее время четко определены 4 основных генетических типа медуллобластомы, имеющие множество подтипов, в связи с чем выдвинуты некоторые гипотезы о диэскалации терапии. Данные о влиянии генетических типов на лечение ограничиваются единичными исследованиями, и окончательных утвержденных заключений, согласно выдвинутым гипотезам в рекомендательных материалах не отражены. Relevance: Medulloblastoma is one of the most common malignant neoplasms of the central nervous system in childhood. The genetic characteristics of the disease may play an important role in determining treatment approaches, but this aspect has not been sufficiently studied to date. Objective: General characteristics of current information about the genetic variants of medulloblastoma in the context of the possibility of purposeful formation of a treatment trajectory. Search strategy: A number of original publications and reviews in the field of research for 2012-2022 were analysed, but we also included publications earlier than 2012, since they contain information about this pathology in childhood and classical basic approaches in the therapy and stratification of the disease. The selection of publications was carried out in accordance with the purpose of the review - the most complete and compact characterization of the genetics of medulloblastoma in accordance with modern treatment. Results and Conclusions: In general, there are currently substantial grounds for the development of differentiated approaches to the treatment of MB in children based on various types of side effects on radiation and chemotherapy. However, even in world medicine, the practical use of such approaches is limited. There are currently 4 major genetic types of medulloblastoma with many subtypes, in this connection, some hypotheses have been put forward about the de-escalation of therapy. Data on the effect of genetic types on treatment are limited to single studies, and the final approved conclusions, according to the hypotheses put forward, are not reflected in the recommendation materials. Өзектілігі: Медуллобластома – балалық шақтағы орталық жүйке жүйесінің ең жиі кездесетін қатерлі ісіктерінің бірі. Аурудың генетикалық сипаттамалары емдеу тәсілдерін анықтауда маңызды рөл атқаруы мүмкін, бірақ бұл аспект бүгінгікүнге дейін жеткілікті түрде зерттелмеген. Мақсаты: емдеу траекториясын мақсатты түрде қалыптастыру мүмкіндігі контекстінде медуллобластоманың генетикалық нұсқалары туралы қазіргі ақпараттың жалпы сипаттамасы. Іздеу стратегиясы: 2012-2022 жылдарға арналған ғылыми-зерттеу саласындағы бірқатар түпнұсқа жарияланымдар мен шолулар талданды, бірақ біз сондай-ақ 2012 жылдың бұрын жарияланымдарды енгіздік,...
- 31 October 2022
- Published by Semey Medical University in Наука и здравоохранение
- No. 5(24),p. 166-178
Open AccessГЕНЕТИЧЕСКИЕ ВАРИАНТЫ МЕДУЛЛОБЛАСТОМЫ У ДЕТЕЙ И ПОДХОДЫ К ЕЕ ЛЕЧЕНИЮ. ОБЗОР ЛИТЕРАТУРЫ.
Актуальность:Медуллобластома – одна из наиболее распространенных злокачественных новообразований ЦНС в детском возрасте. Генетические особенности заболевания могут играть важную роль в определении подходов к лечению, но до настоящего времени этот аспект изучен недостаточно. Цель: Общая характеристика современных сведений о генетических вариантах медуллобластомы в контексте возможности целенаправленного формирования траектории лечения. Стратегия поиска: Проведен поиск научных публикаций в поисковых системах PubMed, eLibrary.ru, Google Scholar. Проанализирован ряд оригинальных публикаций и обзоров по направлению исследования за 2012-2022 гг, но также были включены публикации ранее 2012 года, так как они содержат информацию, касательно данной патологии в детском возрасте и классические базовые подходы в терапии и стратификации болезни. Отбор публикаций осуществлялся в соответствии с целью обзора – максимально полной и компактной характеристики генетики медуллобластомы в соответствии с современным лечением. Результаты и выводы: В целом в настоящее время имеются существенные основания для разработки дифференцированных подходов к лечению МБ у детей, основанных на различных видах побочных действий на лучевую и химиотерапию. Однако даже в мировой медицине практическое использование таких подходов ограничено. В настоящее время четко определены 4 основных генетических типа медуллобластомы, имеющие множество подтипов, в связи с чем выдвинуты некоторые гипотезы о диэскалации терапии. Данные о влиянии генетических типов на лечение ограничиваются единичными исследованиями, и окончательных утвержденных заключений, согласно выдвинутым гипотезам в рекомендательных материалах не отражены. Relevance: Medulloblastoma is one of the most common malignant neoplasms of the central nervous system in childhood. The genetic characteristics of the disease may play an important role in determining treatment approaches, but this aspect has not been sufficiently studied to date. Objective: General characteristics of current information about the genetic variants of medulloblastoma in the context of the possibility of purposeful formation of a treatment trajectory. Search strategy: A number of original publications and reviews in the field of research for 2012-2022 were analysed, but we also included publications earlier than 2012, since they contain information about this pathology in childhood and classical basic approaches in the therapy and stratification of the disease. The selection of publications was carried out in accordance with the purpose of the review - the most complete and compact characterization of the genetics of medulloblastoma in accordance with modern treatment. Results and Conclusions: In general, there are currently substantial grounds for the development of differentiated approaches to the treatment of MB in children based on various types of side effects on radiation and chemotherapy. However, even in world medicine, the practical use of such approaches is limited. There are currently 4 major genetic types of medulloblastoma with many subtypes, in this connection, some hypotheses have been put forward about the de-escalation of therapy. Data on the effect of genetic types on treatment are limited to single studies, and the final approved conclusions, according to the hypotheses put forward, are not reflected in the recommendation materials. Өзектілігі: Медуллобластома – балалық шақтағы орталық жүйке жүйесінің ең жиі кездесетін қатерлі ісіктерінің бірі. Аурудың генетикалық сипаттамалары емдеу тәсілдерін анықтауда маңызды рөл атқаруы мүмкін, бірақ бұл аспект бүгінгікүнге дейін жеткілікті түрде зерттелмеген. Мақсаты: емдеу траекториясын мақсатты түрде қалыптастыру мүмкіндігі контекстінде медуллобластоманың генетикалық нұсқалары туралы қазіргі ақпараттың жалпы сипаттамасы. Іздеу стратегиясы: 2012-2022 жылдарға арналған ғылыми-зерттеу саласындағы бірқатар түпнұсқа жарияланымдар мен шолулар талданды, бірақ біз сондай-ақ 2012 жылдың бұрын жарияланымдарды енгіздік,...
- Open Access
- 21 April 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (1) , 180-183
Causes of transfer and mortality in children with oncohematological diseases admitted to the intensive care unit
The last few decades survival rates of children with hematologic malignancies have improved significantly, due to a potentially curative chemotherapy protocols, the expansion of biological knowledge and innovative methods of therapy. However oncohematological pediatric patients are at high risk for rapid clinical deterioration due to numerous factors such as the severity of the underlying condition, interventions toxicity and associated immunosuppression. Using aggressive tactics of therapy with oncohematological diseases in children is also associated with complications and life-threatening events that lead to admission to the pediatric intensive care unit. Historically, these children have been considered as poor candidates for intensive care. Discussions around the transfer of children with hematological malignancies to intensive care units and also the expected prognosis raised complicate and delicate questions, especially from an ethical point of view. Despite the general tendency of improved survival rate, mortality in the intensive care unit on hematological malignancies children, unfortunately, is still high and, in comparison to adults, has remained relatively invariable over the past decades. These findings highlight the necessity for research in this group of patients.
- 21 April 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (1) , 180-183
Open AccessCauses of transfer and mortality in children with oncohematological diseases admitted to the intensive care unit
The last few decades survival rates of children with hematologic malignancies have improved significantly, due to a potentially curative chemotherapy protocols, the expansion of biological knowledge and innovative methods of therapy. However oncohematological pediatric patients are at high risk for rapid clinical deterioration due to numerous factors such as the severity of the underlying condition, interventions toxicity and associated immunosuppression. Using aggressive tactics of therapy with oncohematological diseases in children is also associated with complications and life-threatening events that lead to admission to the pediatric intensive care unit. Historically, these children have been considered as poor candidates for intensive care. Discussions around the transfer of children with hematological malignancies to intensive care units and also the expected prognosis raised complicate and delicate questions, especially from an ethical point of view. Despite the general tendency of improved survival rate, mortality in the intensive care unit on hematological malignancies children, unfortunately, is still high and, in comparison to adults, has remained relatively invariable over the past decades. These findings highlight the necessity for research in this group of patients.
- 18 March 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (1)
Причины перевода и смертности у детей с онкогематологическими заболеваниями, поступивших в отделение интенсивной терапии. Обзор проблемы.
The last few decades survival rates of children with hematologic malignancies have improved significantly, due to a potentially curative chemotherapy protocols, the expansion of biological knowledge and innovative methods of therapy. However oncohematological pediatric patients are at high risk for rapid clinical deterioration due to numerous factors such as the severity of the underlying condition, interventions toxicity and associated immunosuppression. Using aggressive tactics of therapy with oncohematological diseases in children is also associated with complications and life-threatening events that lead to admission to the pediatric intensive care unit. Historically, these children have been considered as poor candidates for intensive care. Discussions around the transfer of children with hematological malignancies to intensive care units and also the expected prognosis raised complicate and delicate questions, especially from an ethical point of view. Despite the general tendency of improved survival rate, mortality in the intensive care unit on hematological malignancies children, unfortunately, is still high and, in comparison to adults, has remained relatively invariable over the past decades. These findings highlight the necessity for research in this group of patients.
- 18 March 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (1)
Причины перевода и смертности у детей с онкогематологическими заболеваниями, поступивших в отделение интенсивной терапии. Обзор проблемы.
The last few decades survival rates of children with hematologic malignancies have improved significantly, due to a potentially curative chemotherapy protocols, the expansion of biological knowledge and innovative methods of therapy. However oncohematological pediatric patients are at high risk for rapid clinical deterioration due to numerous factors such as the severity of the underlying condition, interventions toxicity and associated immunosuppression. Using aggressive tactics of therapy with oncohematological diseases in children is also associated with complications and life-threatening events that lead to admission to the pediatric intensive care unit. Historically, these children have been considered as poor candidates for intensive care. Discussions around the transfer of children with hematological malignancies to intensive care units and also the expected prognosis raised complicate and delicate questions, especially from an ethical point of view. Despite the general tendency of improved survival rate, mortality in the intensive care unit on hematological malignancies children, unfortunately, is still high and, in comparison to adults, has remained relatively invariable over the past decades. These findings highlight the necessity for research in this group of patients.